Antyra, Inc.
Records under this name other than patents Antyra, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Antyra, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,875,741 | Insulin and IGF-1 Receptor Agonists and Antagonists Lapsed on the fee record Ended Apr 5, 2017 · Medium confidence | Lapsed on the fee record | Ended Apr 5, 2017 | Medium confidence |
| US 7,173,005 | Insulin and IGF-1 Receptor Agonists and Antagonists Lapsed on the fee record Ended Feb 6, 2015 · Medium confidence | Lapsed on the fee record | Ended Feb 6, 2015 | Medium confidence |
| US 7,148,193 | Compounds that bind to growth hormone receptor Lapsed on the fee record Ended Dec 12, 2010 · USPTO record | Lapsed on the fee record | Ended Dec 12, 2010 | USPTO record |
| US 7,056,679 | Target specific screening and its use for identifying target binders Lapsed on the fee record Ended Jun 6, 2010 · USPTO record | Lapsed on the fee record | Ended Jun 6, 2010 | USPTO record |
| US 6,387,879 | Compounds that bind growth to hormone receptor Lapsed on the fee record Ended May 14, 2010 · USPTO record | Lapsed on the fee record | Ended May 14, 2010 | USPTO record |